Beta‐catenin–NF‐κB interactions in murine hepatocytes: A complex to die for

Kari Nejak‐Bowen, Alexander Kikuchi, Satdarshan P.S. Monga – 3 September 2012 – Wnt/β‐catenin signaling plays an important role in hepatic homeostasis, especially in liver development, regeneration, and cancer, and loss of β‐catenin signaling is often associated with increased apoptosis. To elucidate how β‐catenin may be regulating hepatocyte survival, we investigated the susceptibility of β‐catenin conditional knockout (KO) mice and their wild‐type (WT) littermates to Fas and tumor necrosis factor‐α (TNF‐α), two common pathways of hepatocyte apoptosis.

Telaprevir‐based triple therapy in liver transplant patients with hepatitis C virus: A 12‐week pilot study providing safety and efficacy data

Christoph R. Werner, Daniel P. Egetemeyr, Ulrich M. Lauer, Silvio Nadalin, Alfred Königsrainer, Nisar P. Malek, Christoph P. Berg – 1 September 2012 – After liver transplantation (LT), the management of recurrent hepatitis C virus (HCV) infections still remains a major challenge. In HCV genotype 1 patients not undergoing transplantation, the introduction of protease inhibitor (PI)–based regimens has increased the sustained virological response rate significantly.

Interferon‐gamma–mediated tissue factor expression contributes to T‐cell‐mediated hepatitis through induction of hypercoagulation in mice

Junko Kato, Tomohiro Okamoto, Hiroyuki Motoyama, Ryosuke Uchiyama, Daniel Kirchhofer, Nico Van Rooijen, Hirayuki Enomoto, Shuhei Nishiguchi, Norifumi Kawada, Jiro Fujimoto, Hiroko Tsutsui – 30 August 2012 – Concanavalin A (Con A) treatment induces severe hepatitis in mice in a manner dependent on T cells, interferon (IFN)‐gamma, and tumor necrosis factor (TNF). Treatment with the anticoagulant heparin protects against hepatitis, despite healthy production of IFN‐γ and TNF. Here, we investigated molecular and cellular mechanisms for hypercoagulation‐mediated hepatitis.

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

Sudeep Tanwar, Paul M. Trembling, Indra N. Guha, Julie Parkes, Philip Kaye, Alastair D. Burt, Stephen D. Ryder, Guruprasad P. Aithal, Christopher P. Day, William M. Rosenberg – 29 August 2012 – Liver biopsy is the reference standard for the detection of nonalcoholic steatohepatitis (NASH) within nonalcoholic fatty liver disease (NAFLD). The aim of this study was to identify a biomarker of NASH in patients without significant fibrosis. In all, 172 patients from two centers with biopsy‐proven NAFLD were included in this study.

Subscribe to